Soleno Therapeutics Under Legal Fire for Clinical Trial Misrepresentations and Investor Concerns

Soleno Therapeutics Faces Legal Scrutiny Over Clinical Trial Misrepresentations

Soleno Therapeutics, Inc. finds itself embroiled in a series of class action lawsuits initiated by multiple law firms, highlighting serious allegations regarding its flagship product, DCCR (diazoxide choline extended-release tablets), marketed as VYKAT XR. The lawsuits, filed against the backdrop of the Securities Exchange Act of 1934, accuse Soleno of making misleading statements about the safety and efficacy of DCCR during its Phase 3 clinical trials. Investors who purchased Soleno’s securities between March 26, 2025, and November 4, 2025, are particularly targeted as they are encouraged to engage with the law firms representing the cases before the May 5, 2026 deadline for filing claims.

Central to the lawsuits are claims that Soleno downplayed significant safety concerns linked to DCCR, potentially compromising the integrity of the clinical data. Notably, the pivotal 16-week randomized withdrawal study, which supported the FDA's approval of DCCR, reportedly involved only 77 participants, raising questions about the soundness of its findings. Additional scrutiny arises from earlier trial data indicating the drug did not meet its primary endpoint for improving hyperphagia, despite purported endorsements regarding its commercial viability. As regulatory and clinical scrutiny mounts, Soleno's management faces increased pressure to provide transparency and clarity about the drug's side effects and overall safety profile.

The implications for Soleno extend beyond the immediate legal challenges, as the allegations could significantly impact investor confidence and the company’s market standing. Adverse events tied to DCCR, including reports of fluid retention and metabolic concerns like prediabetes, have led to reservations among healthcare professionals regarding prescribing the medication. Should the plaintiffs succeed in their cases, Soleno could face reputational harm, potential financial restitution to shareholders, and pressure to reevaluate its clinical trial processes moving forward.

In a broader context, the class action lawsuits represent a critical moment in the evolving landscape of pharmaceutical accountability. With law firms such as Schall Law Firm, DJS Law Group, and Levi & Korsinsky, LLP taking the lead, they signal a growing emphasis on holding biotech firms accountable for transparent communication of drug safety and efficacy data. These legal actions compel other companies within the industry to maintain heightened diligence in their clinical trial methodologies and disclosures, ensuring they meet ethical standards in patient safety and investor relations.

Additionally, the legal recourse made available to affected investors underlines the importance of corporate governance in biotech ventures. Soleno's case serves as a reminder of the potential ramifications when companies misrepresent clinical findings and their implications, as stakeholders increasingly demand integrity and accountability in pharmaceutical innovation.